Paukovcekova S, Krchniakova M, Chlapek P, Neradil J, Skoda J*, Veselska R*
Thiosemicarbazones Can Act Synergistically with Anthracyclines to Downregulate CHEK1 Expression and Induce DNA Damage in Cell Lines Derived from Pediatric Solid Tumors
Int J Mol Sci 2022;23(15), 8549

Kameneva P, Melnikova V I, Kastriti M E, Kurtova A, Kryukov E, Murtazina A, Faure L, Poverennaya I, Artemov A V, Kalinina T S, Kudryashov N V, Bader M, Skoda J, Chlapek P, Curylova L, Sourada L, Neradil J, Tesarova M, Pasqualetti M, Gaspar P, Yakushov V D, Sheftel B I, Zikmund T, Kaiser J, Fried K, Alenina N, Voronezhskaya E E*, Adameyko I*
Serotonin limits generation of chromaffin cells during adrenal organ development
Nat Commun 2022;13(1), 2901

Çoku J, Booth D M, Skoda J, Pedrotty M C, Vogel J, Liu K, Vu A, Carpenter E L, Ye J C, Chen M A, Dunbar P, Scadden E, Yun T D, Nakamaru-Ogiso E, Area-Gomez E, Li Y, Goldsmith K C, Reynolds C P, Hajnoczky G, Hogarty M D*
Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance
EMBO J 2022;41(8):e108272

Krchniakova M, Paukovcekova S, Chlapek P, Neradil J, Skoda J*, Veselska R*
Thiosemicarbazones and selected tyrosine kinase inhibitors synergize in pediatric solid tumors: NDRG1 upregulation and impaired prosurvival signaling in neuroblastoma cells
Front Pharmacol 2022;13:976955. 

Curylova L, Ramos H, Saraiva L*, Skoda J*
Noncanonical roles of p53 in cancer stemness and their implications in sarcomas
Cancer Lett 2022;525:131-145

Macsek P*, Skoda J*, Krchniakova M*, Neradil J*, Veselska R*
Iron-Chelation Treatment by Novel Thiosemicarbazone Targets Major Signaling Pathways in Neuroblastoma.
Int J Mol Sci. 2022; 23(1):376.

Seebacher N A, Krchniakova M, Stacy A E, Skoda J*, Jansson P J*
Tumour Microenvironment Stress Promotes the Development of Drug Resistance
Antioxidants (Basel) 2021;10(11):1801

Mahdal M, Neradil J, Mudry P, Paukovcekova S, Staniczkova Zambo I, Urban J, Macsek P, Pazourek L, Tomas T,  Veselska R*
New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ Signaling
Cancers (Basel).202;13(14):3543.

Paukovcekova S, Skoda J, Neradil J, Mikulenkova E, Chlapek P, Sterba J, Richardson D R, Veselska R*
Novel Thiosemicarbazones Sensitize Pediatric Solid Tumor Cell-Types to Conventional Chemotherapeutics through Multiple Molecular Mechanisms
Cancers 2020,12(12):3781

Mikulenkova E, Neradil J, Vymazal O, Skoda J*, Veselska R
NANOG/NANOGP8 Localizes at the Centrosome and is Spatiotemporally Associated with Centriole Maturation
Cells 2020;9(3):692

Gojo J, Pavelka Z, Zapletalova D, Schmook M T, Mayr L, Madlener S, Kyr M, Vejmelkova K, Smrcka M, Czech T, Dorfer C, Skotakova J, Azizi A A, Chocholous M, Reisinger D, Lastovicka D, Valik D, Haberler C, Peyrl A, Noskova H, Pál K, Jezova M, Veselska R, Kozakova S, Slaby O, Slavc I, Sterba J*
Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic Opportunities
Frontiers in Oncology 2020;9:1436

Polaskova K*, Merta T, Martincekova A, Zapletalova D, Kyr M, Mazanek P, Krenova Z, Mudry P, Jezova M, Tuma J, Skotakova J, Cervinkova I, Valik D, Zdrazilova-Dubska L, Noskova H, Pal K, Slaby O, Fabian P, Kozakova S, Neradil J, Veselska R, Kanderova V, Hrusak O, Freiberger T, Klement G L, Sterba J
Comprehensive Molecular Profiling for Relapsed/Refractory Pediatric Burkitt Lymphomas—Retrospective Analysis of Three Real-Life Clinical Cases—Addressing Issues on Randomization and Customization at the Bedside
Frontiers in Oncology 2020;9:1531

Krchniakova M, Skoda J, Neradil J, Chlapek P, Veselska R
Repurposing tyrosine kinase inhibitors to overcome multidrug resistance in cancer: A focus on transporters and lysosomal sequestration
International Journal of Molecular Sciences 2020;21(9):315

Skoda J*, Neradil J, Zambo I S, Nunukova A, Macsek P, Borankova K, Dobrotkova V, Nemec P, Sterba J, Veselska R*
Serial Xenotransplantation in NSG Mice Promotes a Hybrid Epithelial/Mesenchymal Gene Expression Signature and Stemness in Rhabdomyosarcoma Cells
Cancers 2020;12(1):196

Veselska R*, Jezova M, Kyr M, Mazanek P, Chlapek P, Dobrotkova V, Sterba J
Comparative Analysis of Putative Prognostic and Predictive Markers in Neuroblastomas: High Expression of PBX1 Is Associated With a Poor Response to Induction Therapy
Front Oncol 2019;9:1221

Skoda J, Borankova K, Jansson P J, Huang M L, Veselska R, Richardson D R*
Pharmacological targeting of mitochondria in cancer stem cells: An ancient organelle at the crossroad of novel anti-cancer therapies
Pharmacol Res 2019;139:298-313

Neradil J, Kyr M, Polaskova K, Kren L, Macigova P, Skoda J, Sterba J, Veselska R*
Phospho-Protein Arrays as Effective Tools for Screening Possible Targets for Kinase Inhibitors and Their Use in Precision Pediatric Oncology
Front Oncol 2019;9:930 

Kyr M*, Polaskova K, Kuttnerova Z, Merta T, Neradil J, Berkovcova J, Horky O, Jezova M, Veselska R, Klement G L, Valik D, Sterba J
Individualization of Treatment Improves the Survival of Children With High-Risk Solid Tumors: Comparative Patient Series Analysis in a Real-Life Scenario
Front Oncol 2019;9:644

Gomes S, Raimundo L, Soares J, Loureiro J B, Leao M, Ramos H, Monteiro M N, Lemos A, Moreira J, Pinto M, Chlapek P, Veselska R, Sousa E*, Saraiva L*
New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma
Cancer Lett 2019;446:90-102 

Dobrotkova V, Chlapek P, Jezova M, Adamkova K, Mazanek P, Sterba J, Veselska R*
Prediction of neuroblastoma cell response to treatment with natural or synthetic retinoids using selected protein biomarkers
PLoS One 2019;14(6):e0218269 

Sramek M, Neradil J, Macigova P, Mudry P, Polaskova K, Slaby O, Noskova H, Sterba J, Veselska R*
Effects of Sunitinib and Other Kinase Inhibitors on Cells Harboring a PDGFRB Mutation Associated with Infantile Myofibromatosis
Int J Mol Sci 2018;19(9):2599

Skoda J*, Veselska R
Cancer stem cells in sarcomas: Getting to the stemness core
Biochim Biophys Acta Gen Subj 2018;1862(10):2134-2139

Chlapek P, Slavikova V, Mazanek P, Sterba J, Veselska R*
Why Differentiation Therapy Sometimes Fails: Molecular Mechanisms of Resistance to Retinoids
Int J Mol Sci 2018;19(1):132

Dobrotkova V, Chlapek P, Mazanek P, Sterba J, Veselska R
Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy
BMC Cancer 2018;18(1):1059

Sramek M, Neradil J, Veselska R
Much more than you expected: The non-DHFR-mediated effects of methotrexate
Biochim Biophys Acta Gen Subj 2017;1861(3):499-503

Mudry P*, Slaby O, Neradil J, Soukalova J, Melicharkova K, Rohleder O, Jezova M, Seehofnerova A, Michu E, Veselska R, Sterba J
Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene
BMC Cancer 2017:17(1):119

Chlapek P, Zitterbart K, Kren L, Filipova L, Sterba J, Veselska R*
Uniformity under in vitro conditions: Changes in the phenotype of cancer cell lines derived from different medulloblastoma subgroups
PLoS One 2017;12(2):e0172552

Skoda J, Nunukova A, Loja T, Zambo I, Neradil J, Mudry P, Zitterbart K, Hermanova M, Hampl A, Sterba J, Veselska R*
Cancer stem cell markers in pediatric sarcomas: Sox2 is associated with tumorigenicity in immunodeficient mice
Tumor biology 2016;37(7):9535-9548 

Skoda J, Hermanova M, Loja T, Nemec P, Neradil J, Karasek P, Veselska R*
Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma
PLOS ONE 2016;11(7):e0159255

Sramek M, Neradil J, Sterba J, Veselska R*
Non-DHFR-mediated effects of methotrexate in osteosarcoma cell lines: epigenetic alterations and enhanced cell differentiation
Cancer Cell International 2016;29:16:14

Zambo I, Hermanova M, Zapletalova D, Skoda J, Mudry P, Kyr M, Zitterbart K, Sterba J, Veselska R*
Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas
Cancer Biomarkers 17(1), 107-116 (2016).

Mikulenkova E, Neradil J, Zitterbart K, Sterba J, Veselska R*
Overexpression of the Delta Np73 isoform is associated with centrosome amplification in brain tumor cell lines
Tumor Biology 2015;36(10):7483-7491

Nunukova A, Neradil J, Skoda J, Jaros J, Hampl A, Sterba J, Veselska R*
Atypical nuclear localization of CD133 plasma membrane glycoprotein in rhabdomyosarcoma cell lines
International Journal of Molecular Medicine 2015; 36(1):65-72

Neradil J, Veselska R
Nestin as a marker of cancer stem cells
Cancer Science 2015;106(7):803-811

Neradil J*, Pavlasova G, Sramek M, Kyr M, Veselska R, Sterba J
DHFR-mediated effects of methotrexate in medulloblastoma and osteosarcoma cells: The same outcome of treatment with different doses in sensitive cell lines
Oncology Reports 2015;33(5):2169-2175

Krzyzankova M, Chovanova S, Chlapek P, Radsetoulal M, Neradil J, Zitterbart K, Sterba J, Veselska R*
LOX/COX inhibitors enhance the antineoplastic effects of all-trans retinoic acid in osteosarcoma cell lines
Tumor Biology 2014;35(8):7617-7627

Chlapek P, Neradil J, Redova M, Zitterbart K, Sterba J, Veselska R*
The ATRA-induced differentiation of medulloblastoma cells is enhanced with LOX/COX inhibitors: an analysis of gene expression
Cancer Cell International 2014;13:14:51

Skoda J, Neradil J, Zitterbart K, Sterba J, Veselska R*
EGFR signaling in the HGG-02 glioblastoma cell line with an unusual loss of EGFR gene copy
Oncology Reports 2014;31(1):480-487